Dual mTOR Kinase Inhibitor MLN0128 Sensitizes HR+/HER2+ Breast Cancer Patient-Derived Xenografts to Trastuzumab or Fulvestrant.
Hsu PY, Wu VS, Kanaya N, Petrossian K, Hsu HK, Nguyen D, Schmolze D, Kai M, Liu CY, Lu H, Chu P, Vito CA, Kruper L, Mortimer J, Chen S.
Hsu PY, et al. Among authors: chen s.
Clin Cancer Res. 2018 Jan 15;24(2):395-406. doi: 10.1158/1078-0432.CCR-17-1983. Epub 2017 Oct 27.
Clin Cancer Res. 2018.
PMID: 29079660
Free PMC article.